Pendle has introduced tokenized-stock long positions to its PendleLoop platform, allowing users to access these positions through Aave markets. This new feature expands PendleLoop's capabilities by adding stock exposure alongside its existing leveraged long and short positions with yield looping. Users can now loop Pendle principal tokens and yield-bearing assets from other protocols, enhancing trading flexibility. Incentives are offered to encourage users to take these new positions, building on Pendle's previous launch of fixed-yield products linked to tokenized Nvidia and Tesla stocks.
Pendle's addition of tokenized stock long positions to PendleLoop is presented here with Pluang market data as of Oct 24, 2026 01:31 WIB. For readers following major cryptocurrencies, 43 of 50 priced assets rose while 6 fell today. Notable movers include UNI at Rp129.204 with a 1-day change of +2.60% and a Pluang order activity split of 52% Sell / 48% Buy, SAND at Rp942 with -2.60% change, and GRT at Rp434 with +2.29% change. The most notable figure is UNI's typical hold time on Pluang of 65 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
